A detailed history of Pekin Hardy Strauss, Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Pekin Hardy Strauss, Inc. holds 35,233 shares of ABBV stock, worth $6.04 Million. This represents 0.91% of its overall portfolio holdings.

Number of Shares
35,233
Previous 35,530 0.84%
Holding current value
$6.04 Million
Previous $5.51 Million 16.51%
% of portfolio
0.91%
Previous 0.8%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 02, 2024

SELL
$159.82 - $182.1 $47,466 - $54,083
-297 Reduced 0.84%
35,233 $6.42 Million
Q4 2023

Feb 05, 2024

BUY
$137.6 - $154.97 $48,710 - $54,859
354 Added 1.01%
35,530 $5.51 Million
Q3 2023

Nov 07, 2023

SELL
$133.59 - $154.65 $70,401 - $81,500
-527 Reduced 1.48%
35,176 $5.24 Million
Q2 2023

Aug 08, 2023

SELL
$132.51 - $164.9 $174,648 - $217,338
-1,318 Reduced 3.56%
35,703 $4.81 Million
Q1 2023

May 08, 2023

SELL
$144.61 - $166.54 $52,059 - $59,954
-360 Reduced 0.96%
37,021 $5.9 Million
Q4 2022

Feb 13, 2023

SELL
$138.31 - $165.87 $49,238 - $59,049
-356 Reduced 0.94%
37,381 $6.04 Million
Q3 2022

Nov 09, 2022

SELL
$134.21 - $153.93 $36,505 - $41,868
-272 Reduced 0.72%
37,737 $5.07 Million
Q2 2022

Aug 05, 2022

BUY
$137.62 - $174.96 $27,936 - $35,516
203 Added 0.54%
38,009 $5.82 Million
Q1 2022

May 13, 2022

SELL
$131.98 - $163.75 $178,964 - $222,045
-1,356 Reduced 3.46%
37,806 $6.13 Million
Q4 2021

Feb 08, 2022

BUY
$107.43 - $135.93 $4,189 - $5,301
39 Added 0.1%
39,162 $5.3 Million
Q3 2021

Nov 12, 2021

SELL
$106.4 - $120.78 $38,516 - $43,722
-362 Reduced 0.92%
39,123 $4.22 Million
Q2 2021

Aug 12, 2021

SELL
$105.21 - $117.21 $631 - $703
-6 Reduced 0.02%
39,485 $4.45 Million
Q1 2021

May 13, 2021

SELL
$102.3 - $112.62 $17,186 - $18,920
-168 Reduced 0.42%
39,491 $4.27 Million
Q4 2020

Feb 11, 2021

BUY
$80.49 - $108.67 $142,064 - $191,802
1,765 Added 4.66%
39,659 $4.25 Million
Q3 2020

Nov 12, 2020

BUY
$85.91 - $100.83 $29,037 - $34,080
338 Added 0.9%
37,894 $3.32 Million
Q2 2020

Aug 10, 2020

BUY
$73.37 - $98.18 $118,419 - $158,462
1,614 Added 4.49%
37,556 $3.69 Million
Q1 2020

May 11, 2020

SELL
$64.5 - $97.79 $150,091 - $227,557
-2,327 Reduced 6.08%
35,942 $2.74 Million
Q4 2019

Feb 12, 2020

BUY
$72.13 - $90.25 $92,975 - $116,332
1,289 Added 3.49%
38,269 $3.39 Million
Q3 2019

Nov 12, 2019

SELL
$62.98 - $75.72 $126,967 - $152,651
-2,016 Reduced 5.17%
36,980 $2.8 Million
Q2 2019

Aug 12, 2019

BUY
$65.7 - $83.98 $200,056 - $255,719
3,045 Added 8.47%
38,996 $2.84 Million
Q1 2019

May 14, 2019

BUY
$77.14 - $90.79 $15,659 - $18,430
203 Added 0.57%
35,951 $2.9 Million
Q4 2018

Feb 12, 2019

SELL
$77.85 - $96.01 $34,876 - $43,012
-448 Reduced 1.24%
35,748 $3.3 Million
Q3 2018

Nov 02, 2018

SELL
$88.91 - $98.84 $103,669 - $115,247
-1,166 Reduced 3.12%
36,196 $3.42 Million
Q2 2018

Aug 03, 2018

SELL
$89.78 - $106.23 $109,711 - $129,813
-1,222 Reduced 3.17%
37,362 $3.46 Million
Q1 2018

May 01, 2018

SELL
$92.01 - $123.21 $1.1 Million - $1.47 Million
-11,939 Reduced 23.63%
38,584 $0
Q4 2017

Feb 02, 2018

SELL
$89.56 - $98.21 $147,594 - $161,850
-1,648 Reduced 3.16%
50,523 $0
Q3 2017

Nov 03, 2017

BUY
$69.85 - $89.22 $3.64 Million - $4.65 Million
52,171
52,171 $4.64 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $303B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Pekin Hardy Strauss, Inc. Portfolio

Follow Pekin Hardy Strauss, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pekin Hardy Strauss, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Pekin Hardy Strauss, Inc. with notifications on news.